SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
HGSI Analysis & Videos »
HGSI: Bull or Bear?
Extreme FDA Calendar Trades: 18 Stocks Under $5
HGSI
|
|
|
-17.01%
in
6 days
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
FDA Calendar Updates: BDSI, SVNT Deadlines Approach
HGSI
|
|
|
+0.00%
in
12 hours
(closed on 06/12/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
Bullish on HGSI ...
HGSI
|
|
|
+89.68%
in
83 days
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The companyÂ’s clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an e...
|
Emerging Biotech & Pharma Index: 36 More Companies
HGSI
|
|
|
+50.00%
in
111 days
(closed on 03/15/09)
<> 
The accompanying table [click to enlarge or download] includes the 36 remaining companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff.
However, several of the companies included in the remaining group of 36 have been in the news recently due to FDA related news . Late last week, Ligand Phar...
|
People Bullish on HGSI
People Bearish on HGSI
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on HGSI |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Human Genome Sciences Inc
- Answers.com
